£395 / $690 / €495
Do you need to know what is happening in the drugs and R&D pipeline for:
Many of these disorders and conditions are widespread in society. Patient populations for specific diseases are often low, and several have no cure or really effective symptomatic treatment. Opportunities exist for effective and safe high-return low-volume products. For pharmaceutical company executives and researchers, staying in touch with the latest twists and turns involving companies and research can be a time-consuming exercise. That is why this new, regularly updated online information service is essential.
Endometabolic Drug News provides:
Every day, Espicom’s researchers and editors
These days we all suffer from information overload. By focusing specifically on this key sector, the newly launched Endometabolic Drug News service will deliver the information you need in a timely, flexible and convenient format.
Start your subscription today!
Endometabolic Drug News is available exclusively by subscription and provides:
Cost-effective multi-user distribution deals means the service can be used widely by colleagues in your organisation – contact firstname.lastname@example.org for details, alternatively you can use our contact us page.